American Society of Hematology Annual Meeting & Exposition (ASH)

Merryman provided background for the study design investigating patients with relapsed or refractory diffuse large B-cell lymphoma.

The goal of the CARTITUDE-1 study was to evaluate the use of ciltacabtagene autoleucel (cilta-cel; JNJ-68284528) chimeric antigen receptor T-cell therapy in heavily pretreated patients with relapsed or refractory multiple myeloma.

The study was designed to evaluate the use of ciltacabtagene autoleucel in patients with relapsed or refractory multiple myeloma in the United States.

The interview features comments on the emergence of T-cell engagers for therapy in patients with multiple myeloma made during the 2020 ASH Meeting & Exposition.

Wolf touched on the implications of results from a study investigating outcomes when making clinical decisions based on the MRD status of patients with multiple myeloma.

A study of the effect of intravenous immunoglobulin (IVIG) on infections in patients with multiple myeloma receiving daratumumab indicated that hypogammaglobulinemia was nearly universal during treatment, suggesting a role for IVIG.

The director of clinical research in the Center for Cancer Care at White Plains Hospital explained the design of the study which evaluated diabetic versus nondiabetic patients enrolled in the CONNECT Multiple Myeloma Registry.

The expert from the Levine Cancer Institute discussed the findings from an updated analysis of the phase 2 GRIFFIN Trial for patients with newly diagnosed multiple myeloma.

Wolf discussed the decisions to change therapy based on the MRD status of patients with multiple myeloma.

Patients with aggressive lymphomas had a sharp increase in quality of life from time of diagnosis until 1 year later.

The allogeneic off-the-shelf CD22-directed T-cell product, UCART22, showed early signs of activity and no evidence of unexpected toxicities for adult patients with relapsed/refractory CD22-positive B-cell acute lymphoblastic leukemia.

The clinical researcher spoke about what she hopes will occur in multiple myeloma research over the next 5 years.

Wolf discusses the potential for emerging next-generation CAR T-cell treatment and the future of treating patients with multiple myeloma.

The hematology and oncology fellow at the Icahn School of Medicine at Mount Sinai discussed exciting treatment options for patients with multiple myeloma that are being presented at ASH this year.

The clinical researcher spoke about the research that she is most excited to review at ASH this year.

Patients with hematologic malignancies were found to be at increased risk for significant morbidity and mortality from COVID-19, and the risk of death appeared to be greatest in those who were older, had more severe infection, a poorer prognosis, or who decided to forego intensive treatment.

Findings from a preclinical study suggested ALVR109 could be a safe and effective treatment for the coronavirus disease 2019.

A phase 1 trial found that MEDI-570 demonstrated clinical activity with durable responses, as well as acceptable safety and tolerability in patients with relapsed or refractory angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma.

The lymphoma expert spoke about the research being presented at the 2020 ASH Annual Meeting and what he believes has the potential to be most influential for treating this patient population.

Idecabtagene vicleucel yielded a clinically meaningful improvements in the quality-of-life of triple-class exposed patients with relapsed/refractory multiple myeloma.

Patients with heavily pretreated multiple myeloma maintained durable responses with idecabtagene vicleucel, according to updated findings presented from the phase 1 CRB-401 trial.

The CAR T-cell therapy elicited a 92% ORR, with high rates of durable responses in patients with indolent non-Hodgkin lymphoma.

Treatment with the oral agent showed sustained health-related quality of life compared with placebo in patients with acute myeloid leukemia, according to results of the phase 3 QUAZAR AML-001 trial.

A novel CD20xCD3 bispecific antibody, odronextamab, continues to show intriguing antitumor activity and an acceptable safety profile in patients with relapsed/refractory B-cell non-Hodgkin lymphoma, including those who have previously received chimeric antigen receptor T-cell therapy.

The leukemia expert discussed exciting research being presented at this year’s ASH Annual Meeting.

Treatment with the CAR T-cell therapy ciltacabtagene autoleucel led to a high response rate and an acceptable safety profile at the recommended phase 2 dose in patients with relapsed or refractory multiple myeloma.

The telomerase inhibitor demonstrated improved overall survival spleen response, and symptom response in patients with myelofibrosis.

The phase 3 BOSTON study demonstrated superior PFS and ORR with selinexor (Xpovio), bortezomib (Velcade), and dexamethasone in patients with relapsed/refractory multiple myeloma.

Study results showed that adding navitoclax to ruxolitinib resulted in a clinically meaningful improvement in spleen volume and total symptom score in patients with myelofibrosis who no longer benefited from prior ruxolitinib therapy.

Treatment with momelotinib improved overall survival and sustained efficacy outcomes in patients with intermediate- or high-risk myelofibrosis.